Dominic Piscitelli
2022 - Oric Pharmaceuticals
In 2022, Dominic Piscitelli earned a total compensation of $1.9M as Chief Financial Officer at Oric Pharmaceuticals, a 25% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $196,623 |
|---|---|
| Option Awards | $1,110,821 |
| Salary | $418,348 |
| Stock Awards | $171,825 |
| Other | $21,942 |
| Total | $1,919,559 |
Piscitelli received $1.1M in option awards, accounting for 58% of the total pay in 2022.
Piscitelli also received $196.6K in non-equity incentive plan, $418.3K in salary, $171.8K in stock awards and $21.9K in other compensation.
Rankings
In 2022, Dominic Piscitelli's compensation ranked 1,811th out of 5,625 executives tracked by ExecPay. In other words, Piscitelli earned more than 67.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,811 out of 5,625 | 68th |
Division Manufacturing | 947 out of 3,053 | 69th |
Major group Chemicals And Allied Products | 383 out of 1,380 | 72nd |
Industry group Drugs | 349 out of 1,281 | 73rd |
Industry Pharmaceutical Preparations | 250 out of 927 | 73rd |
Source: SEC filing on April 26, 2023.
Piscitelli's colleagues
We found two more compensation records of executives who worked with Dominic Piscitelli at Oric Pharmaceuticals in 2022.
News
Oric Pharmaceuticals CEO Jacob Chacko's 2023 pay falls 28% to $3.2M
April 24, 2024
Oric Pharmaceuticals CEO Jacob Chacko's 2022 pay falls 37% to $4.4M
April 26, 2023
Oric Pharmaceuticals CEO Jacob Chacko's 2021 pay rises 19% to $7M
April 27, 2022
Oric Pharmaceuticals CEO Jacob Chacko's 2020 pay jumps 774% to $5.9M
April 26, 2021
ANAPTYSBIO CEO Hamza Suria's 2019 pay jumps 54% to $7.9M
April 27, 2020
ANAPTYSBIO CEO Hamza Suria's 2018 pay jumps 28% to $5.1M
April 26, 2019